Intelligence Profile
Clinical Applications
Bremelanotide (PT-141) is primarily indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The compound has undergone extensive clinical evaluation for this specific indication, with multiple completed Phase 2 and Phase 3 trials.
Primary Clinical Use
Hypoactive Sexual Desire Disorder in Premenopausal Women: The most well-established clinical application is for treating HSDD in premenopausal women. Two completed Phase 3 clinical trials (NCT02338960 and NCT02333071) have evaluated bremelanotide's efficacy and safety for this indication. These pivotal studies formed the basis for regulatory approval, demonstrating the compound's ability to increase sexual desire and reduce associated distress in this patient population.
Additional Areas of Investigation
Female Sexual Arousal Disorder: A Phase 2 study (NCT01382719) investigated bremelanotide's effects on both female sexual arousal disorder and HSDD, suggesting potential broader applications within female sexual dysfunction.
Potential Use in Men: Recent clinical literature has begun exploring whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, though this remains investigational and is not currently an approved indication.
Cancer-Related Sexual Dysfunction: Emerging evidence suggests potential applications for managing sexual health concerns in cancer patients, particularly those with breast and gynecologic cancers experiencing treatment-related sexual dysfunction from endocrine therapies.
Mechanism and Therapeutic Context
Bremelanotide works through melanocortin receptor pathways, representing a novel therapeutic approach distinct from traditional hormonal treatments for sexual dysfunction. The compound is part of a broader category of therapeutic peptides being investigated for various applications in aging and sexual health.
Evidence Limitations
While the primary indication for HSDD in premenopausal women is well-supported by Phase 3 trial data, evidence for other potential applications remains limited to early-phase studies or theoretical considerations. The clinical evidence for use in men or specific cancer populations requires further investigation.
This information is for educational purposes only and should not replace consultation with a healthcare provider for individual medical decisions.